round button
Leave a message

亚太莱伯先天性黑蒙市场 – 行业趋势和 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

亚太莱伯先天性黑蒙市场 – 行业趋势和 2029 年预测

  • Pharmaceutical
  • Published Report
  • Apr 2022
  • Asia-Pacific
  • 350 页面
  • 桌子數: 196
  • 图号: 37

亚太地区莱伯先天性黑蒙市场,按疾病类型(婴儿型、青少年型和其他)、类型(治疗和诊断)、最终用户(医院、专科诊所、门诊手术中心、家庭医疗保健和其他)、分销渠道(直接招标和零售销售)行业趋势和预测到 2029 年。

亚太莱伯先天性黑蒙症市场

市场分析和见解

亚太地区莱伯先天性黑蒙市场受到多种因素的推动,例如糖尿病和胃肠道疾病等慢性病的患病率上升、新兴企业数量不断增加以及输液泵家庭护理服务的普及,这些因素提高了市场需求,此外,研发投入不断增加也推动了市场增长。目前,正在进行各种研究,预计这将为制造商创造竞争优势,以开发新的创新型莱伯先天性黑蒙治疗方法和疗法,预计这将为莱伯先天性黑蒙市场提供各种其他机会。然而,政府对输液治疗期间批准和设备错误的严格规定预计将阻碍增长。

莱伯先天性黑蒙症市场

莱伯先天性黑蒙症市场

亚太地区莱伯先天性黑蒙市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息,分析了新兴收入来源、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情景,请联系我们获取分析师简报,我们的团队将帮助您创建收入影响解决方案,以实现您的预​​期目标。各地区发展中国家零售单位的可扩展性和业务扩展以及与供应商合作安全分销机器和药品是推动预测期内市场需求的主要驱动力。

亚太地区莱伯先天性黑蒙症市场支持并旨在减少疾病的进展。Data Bridge Market Research 分析,在 2022 年至 2029 年的预测期内,亚太地区莱伯先天性黑蒙症市场将以 3.7% 的复合年增长率增长。

报告指标

细节

预测期

2022 至 2029 年

基准年

2021

历史岁月

2020(可定制至 2019 - 2014)

定量单位

收入(百万美元),定价(美元)

涵盖的领域

按疾病类型(婴儿型、青少年型及其他)、类型(治疗、诊断)、最终用户(医院、专科诊所、门诊手术中心、家庭医疗保健及其他)、分销渠道(直接招标和零售)

覆盖国家

By Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific)

Market Players Covered

Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE N.V., Optos, Metrovision, Blue Print Genetics Oy (A Subsidiary of Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc. , Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc. among others.

Asia-Pacific Leber Congenital Amaurosis Market Dynamics

Drivers

  • Increase in incidence and prevalence of rpe65 gene-mediated in retinal diseases

Inherited retinal dystrophies (IRDs) represent a genetically diverse group of progressive, visually debilitating diseases. Adult and pediatric patients with vision loss due to IRD caused by biallelic mutations in the 65-kDa retinal pigment epithelium (RPE65) gene are often clinically diagnosed as retinitis pigmentosa (RP), and Leber congenital amaurosis (LCA).

Leber congenital amaurosis (LCA) is an eye disorder that primarily affects the retina. LCA is characterized by severe visual impairment from birth or the first few months of life, roving eye movements or nystagmus, poor pupillary light responses, oculo digital sign (poking, rubbing, and/or pressing of the eyes), and undetectable or severely abnormal full-field electroretinogram (ERG). LCA is usually inherited as an autosomal recessive genetic condition.

  • Increase in pipeline products and clinical trials

The continuous innovation for the treatment of inherited retinal diseases and Leber congenital amaurosis disorder has the potential to positively impact the market as the size of the market will increase, when these products will have approved in the Asia-Pacific market. Due to no pharmacological treatments for the LCA the major market players are continuously innovating the treatment or investing in the R&D for the treatment. Various ongoing clinical trials are recruiting worldwide to find the mechanism of diseases for treatment.

Opportunities

  •  Increase in government initiatives toward leber congenital amaurosis

According to WHO, the prevalence of monogenic IRDs is it affects about 1 in 40,000 newborns South Americaly. To prevent these, the government of several countries across the globe have taken initiatives.

The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the Asia-Pacific leber congenital amaurosis market.

Restraints/Challenges

The cost of the product plays a major factor in the market. In the inherited retinal diseases market, it is generally observed that the cost of the products is highly sophisticated, need to be precise, and other specifications increase the product's cost.

The high cost of the treatment is due to the various checkpoints of the treatment along with the use of high-tech modalities to perform such treatment procedures.

However, the hospital care further adds to the cost of the leber congenital amaurosis. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with leber congenital amaurosis treatment and diagnosis is expected to restrain the Asia-Pacific leber congenital amaurosis market growth.

However, every country is bounded by the guidelines regulated by different authorities which are expected to act as a challenge to the growth of the Asia-Pacific leber congenital amaurosis market.

Recent Developments

  • In November 2021, REGENXBIO Inc.  Announced the closing of its Collaboration and License Agreement with AbbVie to develop and commercialize RGX-314, potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.
  • In June 2020, SparingVision, a biotechnology company specializing in the research and development of innovative therapies for the treatment of hereditary retinal degenerative diseases such as retinitis pigmentosa, announced the decision of the European Commission to grant Orphan Drug Designation for SPVN06 for the treatment of inherited retinal dystrophies. The decision is based on a positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).

Asia-Pacific Leber Congenital Amaurosis Market Segmentation

Asia-Pacific leber congenital amaurosis market is categorized into disease type, type, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Disease Type

On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type & others

Type

根据类型,亚太地区莱伯先天性黑蒙市场细分为诊断和治疗。诊断部分进一步细分为临床诊断和基因诊断。临床诊断进一步细分为临床眼科检查、视野测试、零售成像和电生理测试。临床诊断细分为电生理测试、视网膜成像、视野测试和临床眼科检查。电生理测试细分为全视野视网膜电图 (ERG) 和暗适应测量 (DA)。视网膜成像细分为光学相干断层扫描 (OCT)、眼底自发荧光成像 (FAF)、扫描激光检眼镜 (SLO) 和自适应光学 (AO) 成像和传统彩色眼底成像。视野测试细分为计算机化视野测试和手动视野测试。临床检查细分为裂隙灯、间接检眼镜、屈光测试和散瞳检查。治疗领域进一步细分为基因治疗、视网膜治疗、神经保护剂和其他。基因治疗进一步细分为 luxturna 和其他。神经保护剂进一步细分为维生素 A 棕榈酸酯、二十二碳六烯酸 (DHA)、叶黄素和其他。

最终用户

  • 医院
  • 专科诊所
  • 门诊手术中心
  • 家庭医疗保健
  • 其他的

根据最终用户,亚太地区莱伯先天性黑蒙市场分为医院、专科诊所、门诊手术中心、家庭医疗保健和其他。

分销渠道

  • 零售销售
  • 直接招标

莱伯先天性黑蒙症市场

根据分销渠道,亚太地区莱伯先天性黑蒙市场细分为零售销售、直接招标。

莱伯先天性黑蒙症市场 区域分析/见解

对莱伯先天性黑蒙市场进行了分析,并按国家、疾病类型、类型、最终用户和分销渠道提供了市场规模洞察和趋势。

莱伯先天性黑蒙市场报告涵盖的国家包括日本、中国、韩国、印度、澳大利亚、泰国、马来西亚、新加坡、印度尼西亚、越南、菲律宾和亚太地区其他地区。

在亚太地区,由于发展中地区技术进步的加快,中国有望占据主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和莱伯先天性黑蒙市场 份额分析

亚太地区莱伯先天性黑蒙市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、亚太地区业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对莱伯先天性黑蒙市场的关注有关。

一些主要的市场参与者包括 Invitae Corporation、Spark Therapeutics, Inc.、LKC Technologies、CENTOGENE NV、Optos、Metrovision、Blue Print Genetics Oy (Quest Diagnostics 的子公司)、CD Genomics、ProQR Therapeutics、OCUGEN, INC.、MeiraGTx Limited、Coave Therapeutics、IVERIC bio, Inc.、Atsena Therapeutics、Editas Medicine、Eluminex Biosciences、Okuvision、Astellas Pharma Inc.、Allergan、agtc、Gyroscope Therapeutics Limited、SparingVision、Kubota Pharmaceutical Holdings Co. Ltd.、REGENXBIO Inc. 等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析以及主要(行业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、亚太地区与地区以及供应商份额分析。如有进一步询问,请要求分析师致电。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 DISEASE TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PIPELINE ANALYSIS FOR ASIA PACIFIC LEBER CONGENTIAL AMAUROSIS MARKET

4.2 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS

4.3 PESTEL ANALYSIS

4.4 PORTERS FIVE FORCES

5 EPIDEMIOLOGY

6 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES

6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS

6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER

6.2 RESTRAINTS

6.2.1 LACK OF QUALIFIED PROFESSIONALS

6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE

6.3 OPPORTUNITIES

6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS

6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE

6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT

6.4 CHALLENGES

6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY

6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS

7 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE

7.1 OVERVIEW

7.2 INFANTILE TYPE

7.3 JUVENILE TYPE

7.4 OTHERS

8 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE

8.1 OVERVIEW

8.2 THERAPY

8.2.1 GENE THERAPY

8.2.1.1 LUXTURNA

8.2.2 RETINAL PROSTHETIC

8.2.3 NEUROPROTECTIVE AGENTS

8.2.3.1 VITAMIN A PALMITATE

8.2.3.2 DOCOSAHEXAENOIC ACID

8.2.3.3 LUTEIN

8.2.3.4 OTHERS

8.2.4 OTHERS

8.3 DIAGNOSIS

8.3.1 CLINICAL DIAGNOSIS

8.3.1.1 ELECTROPHYSIOLOGICAL TESTS

8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG)

8.3.1.1.2 DARK ADAPTOMETRY (DA)

8.3.1.2 RETINAL IMAGING

8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)

8.3.1.2.2 FUNDUS AUTOFLUORESCENCE

8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO)

8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING

8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING

8.3.1.3 VISUAL FIELD TEST

8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS

8.3.1.3.2 MANUAL FIELD TEST

8.3.1.4 CLINICAL EYE EXAMINATION

8.3.1.4.1 SLIT LAMP

8.3.1.4.2 INDIRECT OPHTHALMOSCOPY

8.3.1.4.3 REFRACTION TEST

8.3.1.4.4 DILATION EXAM

8.3.1.5 OTHERS

8.3.2 GENETIC DIAGNOSIS

9 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 SPECIALITY CLINICS

9.4 AMBULATORY SURGICAL CENTERS

9.5 HOME HEALTHCARE

9.6 OTHERS

10 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 RETAIL SALES

10.2.1.1 HOSPITAL PHARMACIES

10.2.1.2 RETAIL PHARMACIES

10.2.1.3 OTHERS

10.3 DIRECT TENDER

11 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY REGION

11.1 ASIA-PACIFIC

11.1.1 CHINA

11.1.2 JAPAN

11.1.3 INDIA

11.1.4 SOUTH KOREA

11.1.5 AUSTRALIA

11.1.6 SINGAPORE

11.1.7 THAILAND

11.1.8 INDONESIA

11.1.9 PHILIPPINES

11.1.10 MALAYSIA

11.1.11 VIETNAM

11.1.12 REST OF ASIA-PACIFIC

12 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 SPARK THERAPEUTICS, INC

14.1.1 COMPANY SNAPSHOT

14.1.2 COMPANY SHARE ANALYSIS

14.1.3 PRODUCT PORTFOLIO

14.1.4 RECENT DEVELOPMENT

14.1.4.1 EU AUTHORIZATION

14.2 OPTOS

14.2.1 COMPANY SNAPSHOT

14.2.2 COMPANY SHARE ANALYSIS

14.2.3 PRODUCT PORTFOLIO

14.2.4 RECENT DEVELOPMENT

14.2.4.1 PRODUCT APPROVAL

14.3 CD GENOMICS

14.3.1 COMPANY SNAPSHOT

14.3.2 COMPANY SHARE ANALYSIS

14.3.3 PRODUCT PORTFOLIO

14.3.4 RECENT DEVELOPMENT

14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS)

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.4.5.1 COLLABORATION

14.5 LKC TECHNOLOGIES, INC

14.5.1 COMPANY SNAPSHOT

14.5.2 COMPANY SHARE ANALYSIS

14.5.3 PRODUCT PORTFOLIO

14.5.4 RECENT DEVELOPMENT

14.5.4.1 PRODUCT APPROVAL

14.5.5 PRODUCT APPROVAL

14.6 AGTC

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.6.4.1 AGREEMENT

14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 ASTELLAS PHARMA INC.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENT

14.9 ATSENA THERAPEUTICS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 CENTOGENE N.V.

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENT

14.10.4.1 PRODUCT LAUNCH

14.11 COAVE THERAPEUTICS

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENT

14.12 EDITAS MEDICINE

14.12.1 COMPANY SNAPSHOT

14.12.2 REVENUE ANALYSIS

14.12.3 PRODUCT PORTFOLIO

14.12.4 RECENT DEVELOPMENTS

14.12.4.1 DATA & TRAIL DATA PRESENTATION

14.13 ELUMINEX BIOSCIENCES

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 GYROSCOPE THERAPEUTICS LIMITED

14.14.1 COMPANY SNAPSHOT

14.14.2 PRODUCT PORTFOLIO

14.14.3 RECENT DEVELOPMENTS

14.15 INVITAE CORPORATION

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENTS

14.15.4.1 NEW FACILITY

14.15.4.2 EXPANSION

14.16 IVERIC BIO.

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENT

14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENTS

14.18 MEIRAGTX LIMITED

14.18.1 COMPANY SNAPSHOT

14.18.2 PRODUCT PORTFOLIO

14.18.3 RECENT DEVELOPMENT

14.19 METROVISION

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.19.3.1 FDA CLEARANCE APPROVAL

14.2 OCUGEN INC.

14.20.1 COMPANY SNAPSHOT

14.20.2 PRODUCT PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 OKUVISION

14.21.1 COMPANY SNAPSHOT

14.21.2 PRODUCT PORTFOLIO

14.21.3 RECENT DEVELOPMENTS

14.21.3.1 APPROVAL

14.22 PROQR THERAPEUTICS

14.22.1 COMPANY SNAPSHOT

14.22.2 PRODUCT PORTFOLIO

14.22.3 RECENT DEVELOPMENTS

14.23 REGENXBIO INC.

14.23.1 COMPANY SNAPSHOT

14.23.2 REVENUE ANALYSIS

14.23.3 PRODUCT PORTFOLIO

14.23.4 RECENT DEVELOPMENTS

14.24 SPARINGVISION

14.24.1 COMPANY SNAPSHOT

14.24.2 PRODUCT PORTFOLIO

14.24.3 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

表格列表

TABLE 1 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 2 ASIA PACIFIC INFANTILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC JUVENILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC HOSPITALS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC SPECIALITY CLINICS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC HOME HEALTHCARE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC DIRECT TENDER IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 28 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 29 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 ASIA-PACIFIC THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 ASIA-PACIFIC GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 32 ASIA-PACIFIC NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 ASIA-PACIFIC DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 34 ASIA-PACIFIC CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 35 ASIA-PACIFIC RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 ASIA-PACIFIC ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 ASIA-PACIFIC VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 ASIA-PACIFIC CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 41 ASIA-PACIFIC RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 43 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 CHINA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 CHINA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 46 CHINA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 CHINA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 CHINA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 CHINA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 CHINA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 CHINA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 CHINA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 54 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 55 CHINA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 56 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 57 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 58 JAPAN THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 JAPAN GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 JAPAN NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 JAPAN DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 JAPAN CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 JAPAN RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 JAPAN ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 JAPAN VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 JAPAN CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 68 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 JAPAN RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 70 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 71 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 INDIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 INDIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 INDIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 INDIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 INDIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 INDIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 INDIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 INDIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 INDIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 82 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 83 INDIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 85 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 SOUTH KOREA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 SOUTH KOREA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 88 SOUTH KOREA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 SOUTH KOREA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 90 SOUTH KOREA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 SOUTH KOREA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 SOUTH KOREA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 SOUTH KOREA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 94 SOUTH KOREA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 95 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 96 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 97 SOUTH KOREA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 98 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 99 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 AUSTRALIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 101 AUSTRALIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 AUSTRALIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 AUSTRALIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 AUSTRALIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 AUSTRALIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 AUSTRALIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 107 AUSTRALIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 AUSTRALIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 110 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 111 AUSTRALIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 112 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 113 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 SINGAPORE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 115 SINGAPORE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 SINGAPORE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 117 SINGAPORE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 SINGAPORE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 119 SINGAPORE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 SINGAPORE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 SINGAPORE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 122 SINGAPORE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 123 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 124 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 125 SINGAPORE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 126 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 127 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 THAILAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 129 THAILAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 THAILAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 131 THAILAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 132 THAILAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 133 THAILAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 134 THAILAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 135 THAILAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 136 THAILAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 137 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 138 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 139 THAILAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 140 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 141 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 142 INDONESIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 143 INDONESIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 144 INDONESIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 145 INDONESIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 146 INDONESIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 147 INDONESIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 148 INDONESIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 149 INDONESIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 150 INDONESIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 151 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 152 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 153 INDONESIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 154 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 155 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 156 PHILIPPINES THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 157 PHILIPPINES GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 158 PHILIPPINES NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 159 PHILIPPINES DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 160 PHILIPPINES CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 161 PHILIPPINES RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 162 PHILIPPINES ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 163 PHILIPPINES VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 164 PHILIPPINES CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 165 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 166 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 167 PHILIPPINES RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 168 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 169 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 170 MALAYSIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 171 MALAYSIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 MALAYSIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 173 MALAYSIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 174 MALAYSIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 175 MALAYSIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 176 MALAYSIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 177 MALAYSIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 178 MALAYSIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 179 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 180 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 181 MALAYSIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 182 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 183 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 184 VIETNAM THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 185 VIETNAM GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 186 VIETNAM NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 187 VIETNAM DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 188 VIETNAM CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 189 VIETNAM RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 190 VIETNAM ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 191 VIETNAM VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 192 VIETNAM CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 193 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 194 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 195 VIETNAM RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 196 REST OF ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: END USER GRID

FIGURE 9 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION

FIGURE 11 RISING GOVERNMENT AWARENESS PROGRAMS ABOUT THE INHERITED RETINAL DISEASE IS EXPECTED TO DRIVE THE ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INFANTILE TYPE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET

FIGURE 15 PROPORTION OF RPE65 GENE MUTATION IN CLINICALLY DIAGNOSED LCA PATIENTS

FIGURE 16 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2021

FIGURE 17 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)

FIGURE 18 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, CAGR (2022-2029)

FIGURE 19 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 20 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2021

FIGURE 21 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 22 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 23 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2021

FIGURE 25 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 26 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 27 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 28 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 29 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 30 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 31 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 32 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)

FIGURE 33 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)

FIGURE 34 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 35 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 36 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 37 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Asia-Pacific Leber Congenital Amaurosis Market will be projected to grow at a CAGR of 3.7% during forecast by 2029.
The significant factors flourishing the growth of the Asia-Pacific Leber Congenital Amaurosis Market are Increase in incidence and prevalence of rpe65 gene-mediated in retinal diseases, and Increase in pipeline products and clinical trials.
The major players operating in the Asia-Pacific Leber Congenital Amaurosis Market are Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE N.V., Optos, Metrovision, Blue Print Genetics Oy (A Subsidiary of Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc. , Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc. among others.
The major countries covered in the Asia-Pacific Leber Congenital Amaurosis Market are Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.
a